Canterbury DHB

Context

Levetiracetam (subcutaneous) Information Sheet

Download a printable version of the Levetiracetam (subcutaneous) Information Sheet.

500 mg/5 mL concentrate for injection

Practice points

Background

Levetiracetam is thought to inhibit seizure activity by blocking N-type voltage-gated calcium channels and/or by binding synaptic vesicular protein SV2A and modulating neurotransmitter release. It is effective in a broad range of seizure types.

Indications

Levetiracetam is increasingly used as monotherapy for seizure prophylaxis in patients with primary or metastatic disease. Off-licence use of subcutaneous levetiracetam offers the possibility of maintaining seizure control when the oral route is lost, and there is no IV access. It is a less sedating option than benzodiazepines.

Adverse events

Interactions

Dosing

Administration

In event of seizure

Benzodiazepines remain the first line management for prolonged seizure or status epilepticus.

Advice and support

Within working hours contact the Christchurch Hospital Palliative Care Service on (03) 364 1473, or the Nurse Maude Hospice on (03) 375 4274.

After hours contact the Christchurch Hospital operator on (03) 364 0640 and ask for the palliative care clinician on call.

About this Canterbury DHB document (951896):

Document Owner:

Kate Grundy (see Who's Who)

Last Reviewed:

December 2021

Next Review:

December 2023

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 951896